Below are the most recent publications written about "Antibodies, Bispecific" by people in Profiles.
-
Kalavar M, Sridhar J. Clinical trials and real-world studies examining faricimab and high-dose aflibercept for wet age-related macular degeneration and diabetic macular edema. Curr Opin Ophthalmol. 2025 May 01; 36(3):189-198.
-
Momenaei B, Yonekawa Y, Abril P, McCullough R, Abbey AM. Outcomes of Intravitreal Aflibercept 8 mg in Eyes With Neovascular Age-Related Macular Degeneration Previously Treated With Faricimab. Ophthalmic Surg Lasers Imaging Retina. 2025 04; 56(4):206-211.
-
Palecki J, Bhasin A, Bernstein A, Mille PJ, Tester WJ, Kelly WK, Zarrabi KK. T-Cell redirecting bispecific antibodies: a review of a novel class of immuno-oncology for advanced prostate cancer. Cancer Biol Ther. 2024 12 31; 25(1):2356820.
-
Momenaei B, Wang K, Kazan AS, Oh GJ, Ni RL, Wakabayashi T, Durrani AF, Kuriyan AE, Klufas MA, Garg SJ, Yonekawa Y, Hsu J. Rates of Ocular Adverse Events after Intravitreal Faricimab Injections. Ophthalmol Retina. 2024 03; 8(3):311-313.
-
Pandit SA, Momenaei B, Wakabayashi T, Mansour HA, Vemula S, Durrani AF, Pashaee B, Kazan AS, Ho AC, Klufas M, Regillo C, Yonekawa Y, Hsu J, Kuriyan A, Chiang A. Clinical Outcomes of Faricimab in Patients with Previously Treated Neovascular Age-Related Macular Degeneration. Ophthalmol Retina. 2024 04; 8(4):360-366.
-
Lowe A, Kitchen S, Jennings I, Kitchen DP, Woods TAL, Walker ID. Effects of Emicizumab on APTT, FVIII assays and FVIII Inhibitor assays using different reagents: Results of a UK NEQAS proficiency testing exercise. Haemophilia. 2020 Nov; 26(6):1087-1091.
-
Hess KJ, Patel P, Joshi AM, Kotkiewicz A. Utilization of Emicizumab in Acquired Factor VIII Deficiency. Am J Case Rep. 2020 May 07; 21:e922326.
-
Wagh K, Seaman MS, Zingg M, Fitzsimons T, Barouch DH, Burton DR, Connors M, Ho DD, Mascola JR, Nussenzweig MC, Ravetch J, Gautam R, Martin MA, Montefiori DC, Korber B. Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections. PLoS Pathog. 2018 03; 14(3):e1006860.
-
Abraham TS, Snook AE. The swinging pendulum of cancer immunotherapy personalization. Per Med. 2017 05; 14(3):259-270.
-
Morano WF, Aggarwal A, Love P, Richard SD, Esquivel J, Bowne WB. Intraperitoneal immunotherapy: historical perspectives and modern therapy. Cancer Gene Ther. 2016 Nov; 23(11):373-381.